Amendment To Cervical Cancer Bill Would Require HPV Labeling For Condoms

This article was originally published in The Gray Sheet

01 Nov 1999
News

Executive Summary

Condoms manufactured 180 days after the enactment of breast and cervical cancer treatment legislation pending in the House would require a statement in labeling that condoms do not provide adequate protection against the transmission of human papillomavirus (HPV), according to an amendment unanimously adopted by the House Commerce Committee during its Oct. 29 mark-up of the legislation.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT012500

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT012500

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Amendment To Cervical Cancer Bill Would Require HPV Labeling For Condoms

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert